Anti-HMN1/ MTRNR2L1/ HN1 functional antibody

Anti-HMN1/ MTRNR2L1/ HN1 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to MTRNR2L1/MTRNR2L1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1105-Ab-1/ GM-Tg-hg-SE1105-Ab-2Anti-Human MTRNR2L1 monoclonal antibodyHuman
GM-Tg-rg-SE1105-Ab-1/ GM-Tg-rg-SE1105-Ab-2Anti-Rat MTRNR2L1 monoclonal antibodyRat
GM-Tg-mg-SE1105-Ab-1/ GM-Tg-mg-SE1105-Ab-2Anti-Mouse MTRNR2L1 monoclonal antibodyMouse
GM-Tg-cynog-SE1105-Ab-1/ GM-Tg-cynog-SE1105-Ab-2Anti-Cynomolgus/ Rhesus macaque MTRNR2L1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1105-Ab-1/ GM-Tg-felg-SE1105-Ab-2Anti-Feline MTRNR2L1 monoclonal antibodyFeline
GM-Tg-cang-SE1105-Ab-1/ GM-Tg-cang-SE1105-Ab-2Anti-Canine MTRNR2L1 monoclonal antibodyCanine
GM-Tg-bovg-SE1105-Ab-1/ GM-Tg-bovg-SE1105-Ab-2Anti-Bovine MTRNR2L1 monoclonal antibodyBovine
GM-Tg-equg-SE1105-Ab-1/ GM-Tg-equg-SE1105-Ab-2Anti-Equine MTRNR2L1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1105-Ab-1/ GM-Tg-hg-SE1105-Ab-2; GM-Tg-rg-SE1105-Ab-1/ GM-Tg-rg-SE1105-Ab-2;
GM-Tg-mg-SE1105-Ab-1/ GM-Tg-mg-SE1105-Ab-2; GM-Tg-cynog-SE1105-Ab-1/ GM-Tg-cynog-SE1105-Ab-2;
GM-Tg-felg-SE1105-Ab-1/ GM-Tg-felg-SE1105-Ab-2; GM-Tg-cang-SE1105-Ab-1/ GM-Tg-cang-SE1105-Ab-2;
GM-Tg-bovg-SE1105-Ab-1/ GM-Tg-bovg-SE1105-Ab-2; GM-Tg-equg-SE1105-Ab-1/ GM-Tg-equg-SE1105-Ab-2
Products NameAnti-MTRNR2L1 monoclonal antibody
Formatmab
Target NameMTRNR2L1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MTRNR2L1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1105-Ag-1Recombinant multi-species HMN1/ MTRNR2L1/ HN1 protein
    ORF Viral VectorvGMLP004731human HN1 Lentivirus particle
    ORF Viral VectorpGMLP004731human HN1 Lentivirus plasmid


    Target information

    Target IDGM-SE1105
    Target NameMTRNR2L1
    Gene ID100462977
    Gene Symbol and SynonymsHN1,MTRNR2L1
    Uniprot AccessionP0CJ68
    Uniprot Entry NameHMN1_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000256618
    Target ClassificationN/A

    The target: MTRNR2L1, gene name: MTRNR2L1, also named as HN1. Predicted to enable receptor antagonist activity. Predicted to be involved in negative regulation of execution phase of apoptosis. Predicted to be located in cytoplasm and extracellular region. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.